BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genetics Squared, New Biotech Firm, Closes $1 Million Funding


10/19/2005 5:11:12 PM

ANN ARBOR, Mich., May 5 /PRNewswire/ -- Genetics Squared, a three-year-old biotech firm that uses computers and proprietary technology to advance clinical development of new therapies, announced a $1 million investment from a regional venture capital firm and a private investor.

The funding was made by CrystalPoint Partners, an Ann Arbor-based venture capital firm, and a private investor from out of state. "Genetics Squared has a great deal of promise and its customers are excited about its ability to increase the speed at which new drugs are developed," said CrystalPoint's managing director Wassim Mortada.

"Genetics Squared technology is focused on a significant challenge in product development," explained John Freshley, the firm's newly named president and chief executive officer. "Drugs often fail because only a subset of the patient population benefits from the new drug and there is no way to predict which patients will respond. Genetics Squared has demonstrated that it can attack that problem with its unique and patented analysis approach."

Freshley said the funding will be used to recruit management and new staff, invest in additional technology infrastructure and develop a sales operation for the company.

The technology developed by Genetics Squared enables it to predict drug response based on specific characteristics of individual patients, such as genetic makeup or certain protein activity. This could assist doctors in prescribing the right therapy for patients allowing them to avoid therapies predicted to have a negative response and choose therapies likely to benefit the patient.

About Genetics Squared

Founded in 2002, Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Using patented analysis software, Genetics Squared stratifies patients for disease diagnosis and to inform therapeutic treatment. The company has focused its development effort on product partnerships with biotechnology and pharmaceutical companies with products in late stage clinical trials or already approved to market. For more information, please visit http://www.genetics2.com/ .

Genetics Squared

CONTACT: Jessica Annaloro of Eiler Communications, +1-734-761-3399,Jessica@EilerPR.com , for Genetics Squared



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES